Aprea rises as FDA removes clinical hold on cancer therapy study

Aprea Therapeutics

09/12/2021 15:43

** Shares of biopharma Aprea Therapeutics Inc  APRE.O  up
~4% at $4.27 
    ** U.S. FDA removes full clinical hold on co's study of lead
product candidate, eprenetapopt, in combination with other
cancer drugs for lymphoid malignancies  urn:newsml:reuters.com:*:nGNX4T6Vf5 
    ** Lymphoid malignancies are cancers that originate from
immune system cells
    ** FDA placed this clinical hold in August, citing concerns
related to the safety and efficacy data from a late-stage study
of eprenetapopt  urn:newsml:reuters.com:*:nGNX69Gjc6 
    ** Eprenetapopt being developed by co for different types of
cancers is also currently on clinical hold for treating a type
of blood cancer in combination with cancer drug azacitidine
    ** Including session's moves, stock down ~13.21% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))